# Sorafenib in Urothelium Cancer of Bladder

> **NCT01215266** · PHASE2 · TERMINATED · sponsor: **Association of Urologic Oncology (AUO)** · enrollment: 98 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01215266
- **Lead sponsor:** Association of Urologic Oncology (AUO)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 98 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2011-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01215266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01215266, "Sorafenib in Urothelium Cancer of Bladder". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01215266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*